Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (PLSE) granted equity inducement stock options to two new employees on September 2, 2026, under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards cover an aggregate of 2,200 shares of common stock, with an exercise price of $52.68 per share, equal to the closing price on the grant date. The options vest over four years on a time-based schedule, with one quarter of each award vesting annually, subject to continued employment. The grants were approved by the company’s independent Compensation Committee and remain subject to the plan’s terms and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported that its Board’s Compensation Committee granted equity inducement awards to five new employees under the 2017 Inducement Equity Incentive Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The options, approved and issued on August 13, 2026, cover up to 16,950 shares of common stock in aggregate.
The stock options have an exercise price of $44.92 per share, equal to the closing price on August 13, 2026. Each award vests over four years, with 25% vesting annually, subject to continued employment. The options are governed by the 2017 Inducement Equity Incentive Plan and individual award agreements.
Pulse Biosciences (Nasdaq: PLSE) reported Q2 2026 revenue of $0.4 million from its controlled commercial launch and a GAAP net loss of $24.7 million versus $19.2 million a year earlier. GAAP operating costs rose to $25.7 million, driven mainly by higher clinical and compensation expenses.
Cash and cash equivalents were $101.6 million at June 30, 2026, aided by $46.8 million in Q2 net proceeds from an at-the-market equity program and additional post‑quarter proceeds. NANOPULSE-AF, the U.S. pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation, surpassed the halfway enrollment mark and expanded its target to 164 evaluable patients while still aiming to complete enrollment by early Q4 2026.
The company continued enrollment in the NANOCLAMP-AF pivotal surgical AF study, advanced the PRECISE-BTN benign thyroid nodule trial (expanded to 100 patients and nearing full enrollment), and progressed a first‑in‑human cancer feasibility study. Pulse Biosciences reiterated plans to seek CE Marks for its catheter and surgical AF systems by late 2026, with potential approvals anticipated by mid‑2027.
Pulse Biosciences (Nasdaq: PLSE) will participate in Canaccord Genuity’s 46th Annual Growth Conference in Boston, MA. Company management is scheduled to present in a fireside chat on Tuesday, August 11, at 2:30 p.m. ET. A live and recorded webcast will be accessible via the “Events Calendar and Presentations” section of the company’s investor relations website.
Pulse Biosciences (Nasdaq: PLSE) announced that the pivotal NANOPULSE-AF IDE study evaluating its Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology has surpassed its enrollment midpoint after study initiation in April 2026. The trial uses the company’s nPulse System for pulmonary vein isolation in patients with atrial fibrillation.
According to Pulse Biosciences and study investigators, enrollment momentum is supported by the system’s ease of use, minimal learning curve and integration into existing ablation workflows, as well as prior first-in-human experience. The company plans to provide further commentary on study progress during its earnings conference call on August 6 at 1:30pm PT / 4:30pm ET.
Pulse Biosciences (Nasdaq: PLSE) will report business updates and second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 1:30pm PT / 4:30pm ET, with phone and webcast access for investors.
The call can be joined by dialing 1-800-715-9871 (U.S.) or 1-646-307-1963 (international), using Conference ID 3486060. A live and recorded webcast will be available on the Pulse Biosciences investor website.
Pulse Biosciences (Nasdaq: PLSE) granted equity inducement stock options to three new employees under its 2017 Inducement Equity Incentive Plan, outside the 2017 Equity Incentive Plan. Approved on July 13, 2026, the options cover up to 9,000 shares at an exercise price of $25.89 per share, equal to the closing price that day.
The awards vest over four years, with 25% of each grant vesting annually, contingent on continued employment, and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Pulse Biosciences (Nasdaq: PLSE) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Management is scheduled to present on Wednesday, June 10, at 10:00 am ET.
A live and recorded webcast of the fireside chat will be available on the company’s investor relations website under “Events Calendar and Presentations”.
Pulse Biosciences (Nasdaq: PLSE) reported that Co-Chairmen Robert Duggan and CEO Paul LaViolette purchased company common stock through its at-the-market equity offering program (ATM) during a designated trading window.
The Co-Chairmen acquired 675,233 shares for an aggregate purchase price of approximately $13.3 million.